List of Excipients in Branded Drug TREXALL

Generic Drugs Containing TREXALL

Company	Ingredient	NDC	Excipient
Teva Women's Health Inc	methotrexate	51285-366	ANHYDROUS LACTOSE
Teva Women's Health Inc	methotrexate	51285-366	CELLULOSE, MICROCRYSTALLINE
Teva Women's Health Inc	methotrexate	51285-366	CROSPOVIDONE
Teva Women's Health Inc	methotrexate	51285-366	D&C YELLOW NO. 10 ALUMINUM LAKE
Teva Women's Health Inc	methotrexate	51285-366	FD&C BLUE NO. 1 ALUMINUM LAKE

What are the Most Frequently-Used Excipients in TREXALL?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	D&C YELLOW NO. 10 ALUMINUM LAKE
1	FD&C BLUE NO. 1 ALUMINUM LAKE

TREXALL Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Trexall is a branded oral methotrexate tablet with limited compound-level exclusivity and high generic substitution risk. Its commercial value depends less on basic methotrexate chemistry than on dose flexibility, pediatric usability, safety controls, supply reliability, and differentiated formulations. The most credible opportunities are low-dose pediatric products, ready-to-use oral liquids, orally disintegrating tablets, and packaging systems that reduce dosing errors.

What is Trexall and how is it used?

Trexall contains methotrexate, a folate-antimetabolite used at substantially different doses and schedules across oncology, rheumatoid arthritis, psoriasis, and other inflammatory diseases. The FDA labeling emphasizes that weekly dosing is used for many non-oncology indications and that daily administration can cause fatal toxicity in those settings.[1]

Attribute	Trexall profile
Active ingredient	Methotrexate
Dosage form	Oral tablet
Labeled strengths	5 mg, 7.5 mg, 10 mg, and 15 mg
Major uses	Rheumatoid arthritis, psoriasis, selected neoplastic diseases
Regulatory pathway	Legacy FDA new drug application
Product type	Small-molecule branded tablet
Key safety issue	Severe toxicity from dosing-frequency and dose-selection errors
Generic pathway	Abbreviated New Drug Application, or ANDA
Biosimilar exposure	None; methotrexate is a small molecule
Primary commercial threat	Generic methotrexate tablets and low-cost oral alternatives

Trexall competes with generic methotrexate tablets, injectable methotrexate products, compounded oral liquids, and other disease-modifying antirheumatic drugs. Its brand value is therefore linked to product reliability and prescribing familiarity rather than molecular exclusivity.

What excipients are used in Trexall tablets?

FDA labeling identifies the Trexall tablet excipient system as including lactose, microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate, and colloidal silicon dioxide.[1,2]

Excipient	Likely functional role	Commercial and technical relevance
Lactose	Diluent and tablet bulk	Supports low-dose tablet manufacture; creates a potential lactose-intolerance and formulation-positioning issue
Microcrystalline cellulose	Filler and compression aid	Improves tablet structure and mechanical strength
Povidone	Binder	Supports granule formation and tablet robustness
Sodium starch glycolate	Superdisintegrant	Promotes tablet breakup and dissolution
Magnesium stearate	Lubricant	Reduces manufacturing friction; excessive use can impair dissolution
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and content uniformity

The formulation is conventional for immediate-release tablets. Its commercial weakness is that most listed excipients are widely available and difficult to protect through composition-of-matter or broad formulation claims. A competitor can often develop a bioequivalent product with a different excipient combination.

Why excipient selection matters for methotrexate

Methotrexate tablets contain a pharmacologically potent active ingredient at low dose. Content uniformity, blend homogeneity, tablet weight control, and dissolution performance are central manufacturing risks. Small process changes can have disproportionate consequences when the active dose is low and the therapeutic window is narrow.

Excipient selection must support:

• Uniform distribution of methotrexate throughout the blend
• Reliable low-dose compression
• Rapid and reproducible disintegration
• Chemical and physical stability
• Low variability between strengths
• Acceptable tablet size for pediatric and geriatric users
• Robust performance after packaging and transport

Direct compression may reduce processing steps, but wet granulation can improve blend uniformity and powder handling in low-dose products. The preferred process depends on API particle size, density, electrostatic behavior, excipient grade, and target tablet strength.

What excipient strategies could improve Trexall?

The strongest strategy is not a simple replacement of one conventional excipient. It is a platform approach that improves dose administration and reduces medication errors.

1. Lactose-free tablets

Removing lactose could support patients who avoid lactose and simplify positioning against the existing product. Mannitol, anhydrous dibasic calcium phosphate, silicified microcrystalline cellulose, or selected starch-based fillers could replace lactose.

A lactose-free product would not automatically receive meaningful regulatory exclusivity. Its value would come from a differentiated label, reliable bioequivalence, and pharmacy or institutional demand.

2. Pediatric-friendly oral liquid

A ready-to-use methotrexate oral solution or suspension has the clearest unmet-use-case potential. Pediatric dosing frequently requires weight- or body-surface-area-based calculations, making fixed-dose tablets difficult to use.

A commercial liquid product could incorporate:

• A low-viscosity vehicle for accurate syringe withdrawal
• Taste-masking agents
• A child-resistant, unit-of-use dosing system
• An oral syringe calibrated in milligrams and milliliters
• Preservative control appropriate for the intended shelf life
• Light-protective packaging
• A formulation that remains homogeneous during the labeled in-use period

Methotrexate is hazardous if administered at the wrong frequency. A liquid product should therefore use packaging and labeling that distinguish weekly from daily dosing. A prefilled, unit-dose presentation could reduce manipulation and caregiver calculation errors, although it would raise manufacturing and packaging costs.

3. Orally disintegrating or dispersible tablets

A dispersible tablet could address swallowing difficulty and permit administration in water. The formulation must control dose loss on the container or dosing vessel and maintain acceptable taste.

Potential excipient systems include mannitol-based fillers, crospovidone or sodium starch glycolate, low-level binders, and taste-masking technologies. The main technical barrier is balancing rapid disintegration with adequate mechanical strength during packaging and transport.

4. Dose-flexible tablet platform

The current strength range covers 5 mg through 15 mg, but patients may require intermediate doses. A scored tablet or multiparticulate system could provide more flexible dosing. The design must demonstrate dose uniformity after splitting and avoid confusing tablet appearances across strengths.

A platform using common excipients across multiple strengths could reduce manufacturing complexity and support line extensions. Distinct tablet colors, shapes, and packaging can reduce strength-selection errors.

5. Low-sodium and excipient-minimized formulations

An excipient-minimized product could appeal to patients with specific dietary restrictions or excipient sensitivities. The commercial opportunity is narrower than the pediatric-liquid opportunity, but institutional buyers may value a consistent, simplified formulation.

What formulation patents could protect a Trexall follow-on product?

A follow-on product would have limited protection from conventional excipients alone. Stronger patent positions would require a specific technical relationship between formulation structure and measurable performance.

Potential claim areas include:

Patent strategy	Potential claim subject	Relative strength
Composition	Defined methotrexate concentration and excipient ranges	Moderate if performance is unexpected
Pediatric liquid	Stable concentration, pH range, preservative system, and in-use shelf life	Moderate to strong if supported by stability data
Taste masking	Coated particles, ion-exchange complex, or multiparticulate delivery system	Moderate
Packaging	Unit-dose, child-resistant, light-protective system linked to dosing safety	Moderate
Manufacturing	Low-dose blending, granulation, compression, or segregation-control process	Moderate
Method of use	Administration protocol that reduces dosing errors or improves adherence	Narrow and difficult to enforce
Tablet splitting	Scored tablet with defined dose-uniformity limits after subdivision	Moderate if technically demonstrated

Patent claims that merely recite common excipients at routine concentrations face obviousness and enablement challenges. The most defensible portfolio would combine composition claims with manufacturing, packaging, and method-of-use claims.

When does Trexall lose exclusivity?

Methotrexate is an old small-molecule active ingredient. Compound-level patent exclusivity has expired. Trexall’s commercial protection therefore depends on any product-specific patents, regulatory exclusivity, trademarks, manufacturing controls, and prescriber or payer behavior.

Exclusivity category	Trexall assessment
Methotrexate compound patent	Expired
Orphan-drug exclusivity	Not established for Trexall as a general product
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current product-specific period established here
Product-specific formulation exclusivity	Must be assessed through current FDA records
Orange Book patent protection	Requires review of the current listing for the relevant NDA
Generic substitution risk	High

The FDA Orange Book remains the controlling source for listed patents and associated expiration information.[3] A branded methotrexate tablet cannot rely on the age of the brand name to prevent ANDA competition.

What is the Orange Book status of Trexall?

Trexall is associated with an FDA legacy NDA for methotrexate tablets. Orange Book analysis should focus on:

1. Whether the relevant NDA is listed as approved and marketed.
2. Whether any patent is currently listed against the product.
3. Whether the listed strength and dosage form remain commercially supplied.
4. Whether any patent has a use code that limits the scope of a Paragraph IV challenge.
5. Whether a generic applicant can certify that it will not market for protected uses.

For a plain methotrexate tablet, the principal barrier is usually bioequivalence and regulatory execution rather than a remaining methotrexate compound patent. A product-specific patent could still delay entry if it covers an active formulation, manufacturing process, or protected method of use.

Which companies are challenging Trexall?

Generic methotrexate tablets are commercially available, creating direct substitution pressure. The generic market includes multiple manufacturers and distributors, while branded products compete on availability, labeling, and prescriber familiarity.

A current Paragraph IV assessment requires review of FDA ANDA litigation records, district-court dockets, Federal Circuit decisions, and the Orange Book. The existence of generic methotrexate tablets does not by itself establish a current Paragraph IV challenge to Trexall. Paragraph IV litigation is relevant only if an ANDA applicant certifies that an Orange Book patent is invalid, unenforceable, or not infringed.

What FDA regulatory pathway applies to an improved methotrexate product?

The pathway depends on the proposed product.

Product concept	Likely FDA pathway
Same immediate-release tablet, same strength	ANDA if bioequivalence and pharmaceutical equivalence are feasible
Different excipients with same dosage form	Usually ANDA, subject to product-specific requirements
New oral liquid	ANDA may be possible if an appropriate reference product and equivalence approach exist; otherwise a 505(b)(2) application may be considered
Orally disintegrating tablet	ANDA or 505(b)(2), depending on reference-product and formulation differences
New dosing device or packaging	May be included with the drug application or require device-related review
New indication	Supplemental NDA or 505(b)(2), depending on the evidence and reliance strategy

A 505(b)(2) strategy is more plausible where the proposed product differs materially from the reference tablet in dosage form, concentration, route, device, or clinical use. The pathway can support a differentiated label but usually requires more development than a conventional ANDA.

FDA guidance and the Inactive Ingredient Database are important for assessing excipient precedent, maximum inactive-ingredient levels, and route-specific acceptability.[4,5]

What generic entry risks exist for Trexall?

Generic entry risk is high for standard tablets because:

• Methotrexate is an established small molecule.
• The reference dosage form is conventional.
• Core excipients are widely used.
• Tablet bioequivalence is generally more straightforward than liquid or modified-release equivalence.
• Payers have strong incentives to substitute lower-cost products.
• Hospital and pharmacy buyers usually treat methotrexate tablets as commodity products.

Risk is lower for a differentiated liquid or safety-oriented presentation because formulation, stability, device, and human-factors requirements create additional execution barriers. Those barriers do not eliminate competition. They increase development cost and extend the time required to reach reliable commercial supply.

How strong is the Trexall patent estate?

The underlying methotrexate patent estate is weak because the active ingredient is long established. A product-specific Trexall estate would need to rely on current formulation, manufacturing, packaging, or use patents.

Estate component	Strategic assessment
Active ingredient	Weak or expired
Conventional tablet excipients	Weak unless linked to unexpected performance
Pediatric liquid technology	Potentially defensible
Taste-masking technology	Defensible if non-obvious and technically reproducible
Dose-error-reduction packaging	Potentially valuable, but enforcement may be product-specific
Manufacturing controls	Useful for process protection and quality differentiation
Trademark and brand recognition	Commercially useful but does not block generic approval

The strongest commercial moat would combine a differentiated dosage form with pediatric or high-risk-use labeling, reliable supply, and pharmacy-ready packaging. A patent-only strategy is less attractive than a product-and-service strategy built around dosing safety.

What commercial opportunities exist for Trexall?

Pediatric and specialty pharmacy

Pediatric inflammatory disease and oncology use create demand for flexible dosing. A ready-to-use oral liquid could reduce compounding dependence and improve caregiver administration. Specialty pharmacies may value standardized concentration, tamper-evident packaging, and integrated dosing instructions.

Hospital and health-system contracts

Hospitals may favor products with predictable supply, clear strength differentiation, and packaging that reduces selection errors. Unit-dose tablets or premeasured liquid presentations could support formulary contracting.

International markets

Geographic opportunities depend on local methotrexate shortages, pediatric formulation availability, and national reimbursement. Excipients must be reviewed against regional pharmacopeias and local labeling requirements. Lactose-free and preservative-controlled products may have broader positioning, but local regulatory filings remain necessary.

Contract manufacturing and licensing

A company with a stable methotrexate liquid or taste-masking platform could license:

• Formulation technology
• Regional marketing rights
• Manufacturing rights
• Pediatric development packages
• Dosing-device configurations
• Co-branded specialty-pharmacy products

Licensing value would depend on regulatory readiness, stability data, manufacturing scale, and access to distribution. There is no basis to attribute a current licensing deal to Trexall without a transaction-specific public filing.

Revenue exposure

Trexall-specific revenue is generally not disclosed separately in public financial reporting. Revenue exposure should therefore be modeled from prescription volume, average net price, payer mix, generic substitution, and the proportion of sales in strengths or indications with limited alternatives.

A standard branded tablet has high price erosion risk after generic substitution. A differentiated liquid, dispersible tablet, or safety-packaged product could preserve pricing if it demonstrates a measurable administration or adherence benefit.

What manufacturing and IP barriers affect a new Trexall competitor?

The main manufacturing barriers are low-dose content uniformity, API segregation, dissolution consistency, stability, and safe handling of a cytotoxic or hazardous active ingredient. A liquid introduces further risks involving sedimentation, microbial control, adsorption to dosing components, preservative performance, and in-use stability.

The main IP barriers are narrower:

• Patentability of a conventional excipient combination
• Freedom to operate around taste-masking technologies
• Device and packaging patents
• Manufacturing-process patents
• Use-code restrictions in the Orange Book
• Trademark restrictions involving Trexall branding

A new entrant should prioritize freedom-to-operate analysis around the delivery system and packaging rather than assume that the basic tablet formulation is unprotected.

Key Takeaways

• Trexall is a branded methotrexate tablet with high generic substitution risk.
• Its listed excipients are conventional: lactose, microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate, and colloidal silicon dioxide.
• The strongest commercial opportunity is a ready-to-use pediatric oral liquid with dosing-error controls.
• Lactose-free, dispersible, scored, and unit-dose products offer secondary opportunities.
• Conventional excipient substitution alone is unlikely to create a strong patent position.
• Methotrexate has no biosimilar risk because it is a small molecule.
• Any current patent or Paragraph IV assessment must rely on the live Orange Book and litigation records for the relevant NDA.
• Revenue depends on differentiation because standard methotrexate tablets are exposed to generic price erosion.

FAQs

Can a lactose-free methotrexate tablet replace Trexall commercially?

Yes, but lactose removal alone is unlikely to support premium pricing or strong exclusivity. The product would need reliable bioequivalence, a clear labeling benefit, and distribution access.

Is a methotrexate oral solution more commercially attractive than a tablet?

Usually. An oral solution can address pediatric dosing, swallowing difficulty, and compounding limitations. It also carries higher formulation, stability, packaging, and regulatory-development costs.

Can excipients create FDA exclusivity for a methotrexate product?

Excipients do not create exclusivity by themselves. A novel formulation may support patents or a differentiated 505(b)(2) approval if it produces a legally and clinically meaningful distinction.

Does Trexall have biosimilar competition?

No. Biosimilars apply to biological products. Methotrexate is a chemically synthesized small molecule and is subject to generic-drug competition.

What is the highest-value formulation innovation for methotrexate?

A stable, taste-masked, ready-to-use oral liquid with an integrated dosing device and weekly-dose safety labeling has the strongest combination of patient need, technical differentiation, and commercial potential.

References

1. U.S. Food and Drug Administration. (2015). Trexall (methotrexate tablets) prescribing information. Teva Pharmaceuticals USA, Inc.

2. National Library of Medicine. (n.d.). Trexall- methotrexate sodium tablet, film coated: DailyMed labeling. DailyMed.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

5. U.S. Food and Drug Administration. (2003). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.